What is the 13F Pro Quality Score for BTAI?

13F Pro ranks BioXcel Therapeutics, Inc. (BTAI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BTAI's current score at https://13fpro.ai/company/BTAI (free sign-up required for the full ranking).

Where does 13F Pro source BTAI data?

All BioXcel Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. BioXcel Therapeutics, Inc. files with the SEC under CIK 1720893. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BTAI in?

BioXcel Therapeutics, Inc. (BTAI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BTAI research updated on 13F Pro?

BTAI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BioXcel Therapeutics, Inc.(BTAI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1720893 BTAI stock profile & AI dashboard →

13F Pro Quality Score

6.2/100

Rank #2,952 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why BTAI Scores 6/100

exact factor attribution · 2026-09-11

BTAI's composite is held back by revenue growth and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

-1.4 pts

22th pct

Earnings quality

-1.5 pts

35th pct

Earnings growth

-2.2 pts

5th pct

Shareholder dilution

-2.4 pts

3th pct

Capital efficiency

-4.9 pts

1th pct

Scale

-7.2 pts

2th pct

Profitability

-7.2 pts

2th pct

Free cash flow

-7.3 pts

2th pct

Revenue growth

-9.8 pts

1th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

BTAI Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for BioXcel Therapeutics, Inc. (BTAI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BTAI at 6.2/100 on a 32-signal composite quality model, placing it at rank #2,952 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), BioXcel Therapeutics, Inc. reports quarterly revenue of $182.0K, net income of $-14.7M, free cash flow of $-6.1M. Top institutional holders of BTAI by reported 13-F value include MILLENNIUM MANAGEMENT, OAKTREE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. BTAI trades on the Nasdaq exchange and files with the SEC under CIK 1720893. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BTAI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BioXcel Therapeutics, Inc. directly from SEC EDGAR. BioXcel Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 6 and 37 since 2024, currently 6.2 — a declining long-term trajectory across 11 quarterly and live scoring snapshots.

Revenue

Q2 2026

$182.0K

Net Income

Q2 2026

$-14.7M

Free Cash Flow

Q2 2026

$-6.1M

ROIC

Q2 2026

-43.6%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-71.7% YoY

$642.0KFY 2025

FY22 $375.0KFY23 $1.4MFY24 $2.3MFY25 $642.0K

Net Income

-17.3% YoY

$-69.9MFY 2025

FY22 $-165.8MFY23 $-179.1MFY24 $-59.6MFY25 $-69.9M

Operating Income

+25.0% YoY

$-50.5MFY 2025

FY22 $-159.6MFY23 $-171.8MFY24 $-67.2MFY25 $-50.5M

EPS (Diluted)

+26.9% YoY

$-5.73FY 2025

FY22 $-0.11FY23 $-1.82FY24 $-7.84FY25 $-5.73

Total Assets

+17.2% YoY

$44.9MFY 2025

FY22 $205.9MFY23 $73.7MFY24 $38.3MFY25 $44.9M

Total Debt

+31.2% YoY

$134.5MFY 2025

FY22 $93.1MFY23 $100.6MFY24 $102.5MFY25 $134.5M

Op. Cash Flow

+20.0% YoY

$-57.6MFY 2025

FY22 $-135.3MFY23 $-155.0MFY24 $-72.0MFY25 $-57.6M

Free Cash Flow

+20.0% YoY

$-57.6MFY 2025

FY22 $-135.5MFY23 $-155.0MFY24 $-72.0MFY25 $-57.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$642.0K -71.7%	$2.3M +64.2%	$1.4M +268.0%	$375.0K	—	—
Net Income	$-69.9M -17.3%	$-59.6M +66.7%	$-179.1M -8.0%	$-165.8M -55.0%	$-106.9M -30.1%	$-82.2M
Operating Income	$-50.5M +25.0%	$-67.2M +60.9%	$-171.8M -7.6%	$-159.6M -49.3%	$-106.9M -29.9%	$-82.3M
EPS (Diluted)	$-5.73 +26.9%	$-7.84 -330.4%	$-1.82 -1561.4%	$-0.11 -46.1%	$-0.07 -6.8%	$-0.07
Total Assets	$44.9M +17.2%	$38.3M -48.0%	$73.7M -64.2%	$205.9M -14.0%	$239.4M +8.9%	$219.9M
Total Debt	$134.5M +31.2%	$102.5M +1.9%	$100.6M +8.1%	$93.1M	—	—
Operating Cash Flow	$-57.6M +20.0%	$-72.0M +53.5%	$-155.0M -14.5%	$-135.3M -64.7%	$-82.2M -23.8%	$-66.3M
Free Cash Flow	$-57.6M +20.0%	$-72.0M +53.5%	$-155.0M -14.4%	$-135.5M -64.0%	$-82.6M -23.9%	$-66.7M

Get alerted when BTAI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BioXcel Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BTAI

MILLENNIUM MANAGEMENT LLC
$3.0M2,114,710 sh
OAKTREE CAPITAL MANAGEMENT LP
$1.9M1,380,248 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.3M919,545 sh
Oaktree Fund Advisors, LLC
$346.3K245,585 sh
GEODE CAPITAL MANAGEMENT, LLC
$341.9K242,251 sh
BlackRock, Inc.
$253.0K179,433 sh
UBS Group AG
$222.9K158,065 sh
CITADEL ADVISORS LLC
$210.4K149,220 sh
VANGUARD FIDUCIARY TRUST CO
$193.1K136,937 sh
STATE STREET CORP
$129.9K92,118 sh

Fund	Value	Shares
MILLENNIUM MANAGEMENT LLC	$3.0M	2,114,710
OAKTREE CAPITAL MANAGEMENT LP	$1.9M	1,380,248
VANGUARD CAPITAL MANAGEMENT LLC	$1.3M	919,545
Oaktree Fund Advisors, LLC	$346.3K	245,585
GEODE CAPITAL MANAGEMENT, LLC	$341.9K	242,251
BlackRock, Inc.	$253.0K	179,433
UBS Group AG	$222.9K	158,065
CITADEL ADVISORS LLC	$210.4K	149,220
VANGUARD FIDUCIARY TRUST CO	$193.1K	136,937
STATE STREET CORP	$129.9K	92,118

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BTAI on your watchlist

Track score changes the day BioXcel Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BTAI a good stock to buy?

13F Pro's AI-powered analysis of BioXcel Therapeutics, Inc. (BTAI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BTAI are available on the BTAI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BTAI is classified as a small company.

Which hedge funds own BTAI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BTAI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BioXcel Therapeutics, Inc.'s investment landscape.